Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem

Osteosarcoma is an aggressive bone tumor occurring primarily in pediatric patients. Despite years of intensive research, the outcomes of patients with metastatic disease or those who do not respond to therapy have remained poor and have not changed in the last 30 years. Oncolytic virotherapy is beco...

Descripción completa

Detalles Bibliográficos
Autores: Martinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559, Laspidea, V. (Virginia)|||/items/16d4f649-0742-47dc-a391-881d6cfb978f, Zalacain-Díez, M. (Marta)|||/items/c9a0a606-4b28-4f43-b423-2bd8ca984432, Labiano-Almiñana, S. (Sara)|||/items/65de3442-2f0f-4c20-8e40-43525bb58657, Garcia-Moure, M. (Marc)|||/items/9741d07b-2525-4e98-9bfc-93fc3e869273, Puigdelloses-Vallcorba, M. (Montserrat)|||/items/658120d0-6a3c-4bf3-9446-33a9234f787e, Marrodán-Fernández, L. (Lucía)|||/items/cb588714-8640-4468-a1e4-ea467d9fe714, Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40b, Herrador-Cañete, G. (Guillermo)|||/items/91f6f4a9-1383-4ec6-b17f-a914248ff8b0, Nava-Martín, D. (Daniel) de la|||/items/9d3a254f-7e46-4632-8066-48e55de9acbd, Ausejo-Mauleón, I. (Iker)|||/items/5dc64e9f-8695-4947-a007-886bda06f2a5, Fueyo, J. (Juan)|||/items/a4e5ff79-2565-4461-ab26-34868ff5ff4d, Gomez-Manzano, C. (Candelaria)|||/items/5e8d7495-6be8-46e1-8303-cfd722d30166, Patiño-García, A. (Ana)|||/items/d68c74f1-df22-4e04-9b77-9cf48fd87b46, Alonso-Roldán, M.M. (Marta María)|||/items/b912e21e-f895-4efe-bc4c-de1ca8f36c37
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/116490
Acceso en línea:https://hdl.handle.net/10171/116490
Access Level:acceso abierto
Palabra clave:Oncolytic Adenovirus
Osteosarcoma
Delta-24-ACT
id ES_c194d82c32e2256bc898f8d61ebbb4dc
oai_identifier_str oai:dadun.unav.edu:10171/116490
network_acronym_str ES
network_name_str España
repository_id_str
spelling Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memMartinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559Laspidea, V. (Virginia)|||/items/16d4f649-0742-47dc-a391-881d6cfb978fZalacain-Díez, M. (Marta)|||/items/c9a0a606-4b28-4f43-b423-2bd8ca984432Labiano-Almiñana, S. (Sara)|||/items/65de3442-2f0f-4c20-8e40-43525bb58657Garcia-Moure, M. (Marc)|||/items/9741d07b-2525-4e98-9bfc-93fc3e869273Puigdelloses-Vallcorba, M. (Montserrat)|||/items/658120d0-6a3c-4bf3-9446-33a9234f787eMarrodán-Fernández, L. (Lucía)|||/items/cb588714-8640-4468-a1e4-ea467d9fe714Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40bHerrador-Cañete, G. (Guillermo)|||/items/91f6f4a9-1383-4ec6-b17f-a914248ff8b0Nava-Martín, D. (Daniel) de la|||/items/9d3a254f-7e46-4632-8066-48e55de9acbdAusejo-Mauleón, I. (Iker)|||/items/5dc64e9f-8695-4947-a007-886bda06f2a5Fueyo, J. (Juan)|||/items/a4e5ff79-2565-4461-ab26-34868ff5ff4dGomez-Manzano, C. (Candelaria)|||/items/5e8d7495-6be8-46e1-8303-cfd722d30166Patiño-García, A. (Ana)|||/items/d68c74f1-df22-4e04-9b77-9cf48fd87b46Alonso-Roldán, M.M. (Marta María)|||/items/b912e21e-f895-4efe-bc4c-de1ca8f36c37Oncolytic AdenovirusOsteosarcomaDelta-24-ACTOsteosarcoma is an aggressive bone tumor occurring primarily in pediatric patients. Despite years of intensive research, the outcomes of patients with metastatic disease or those who do not respond to therapy have remained poor and have not changed in the last 30 years. Oncolytic virotherapy is becoming a reality to treat local and metastatic tumors while maintaining a favorable safety profile. Delta-24-ACT is a replicative oncolytic adenovirus engineered to selectively target cancer cells and to potentiate immune responses through expression of the immune costimulatory ligand 4-1BB. This work aimed to assess the antisarcoma effect of Delta-24-ACT. MTS and replication assays were used to quantify the antitumor effects of Delta-24-ACT in vitro in osteosarcoma human and murine cell lines. Evaluation of the in vivo antitumor effect and immune response to Delta-24-ACT was performed in immunocompetent mice bearing the orthotopic K7M2 cell line. Immunophenotyping of the tumor microenvironment was characterized by immunohistochemistry and flow cytometry. In vitro, Delta-24-ACT killed osteosarcoma cells and triggered the production of danger signals. In vivo, local treatment with Delta-24-ACT led to antitumor effects against both the primary tumor and spontaneous metastases in a murine osteosarcoma model. Viral treatment was safe, with no noted toxicity. Delta-24-ACT significantly increased the median survival time of treated mice. Collectively, our data identify Delta-24-ACT administration as an effective and safe therapeutic strategy for patients with local and metastatic osteosarcoma. These results support clinical translation of this viral immunotherapy approach.American Association for Cancer ResearchDadun. Depósito Académico Digital Universidad de Navarra20222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/116490reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1164902026-06-21T12:47:57Z
dc.title.none.fl_str_mv Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
title Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
spellingShingle Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
Martinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559
Oncolytic Adenovirus
Osteosarcoma
Delta-24-ACT
title_short Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
title_full Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
title_fullStr Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
title_full_unstemmed Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
title_sort Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune mem
dc.creator.none.fl_str_mv Martinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559
Laspidea, V. (Virginia)|||/items/16d4f649-0742-47dc-a391-881d6cfb978f
Zalacain-Díez, M. (Marta)|||/items/c9a0a606-4b28-4f43-b423-2bd8ca984432
Labiano-Almiñana, S. (Sara)|||/items/65de3442-2f0f-4c20-8e40-43525bb58657
Garcia-Moure, M. (Marc)|||/items/9741d07b-2525-4e98-9bfc-93fc3e869273
Puigdelloses-Vallcorba, M. (Montserrat)|||/items/658120d0-6a3c-4bf3-9446-33a9234f787e
Marrodán-Fernández, L. (Lucía)|||/items/cb588714-8640-4468-a1e4-ea467d9fe714
Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40b
Herrador-Cañete, G. (Guillermo)|||/items/91f6f4a9-1383-4ec6-b17f-a914248ff8b0
Nava-Martín, D. (Daniel) de la|||/items/9d3a254f-7e46-4632-8066-48e55de9acbd
Ausejo-Mauleón, I. (Iker)|||/items/5dc64e9f-8695-4947-a007-886bda06f2a5
Fueyo, J. (Juan)|||/items/a4e5ff79-2565-4461-ab26-34868ff5ff4d
Gomez-Manzano, C. (Candelaria)|||/items/5e8d7495-6be8-46e1-8303-cfd722d30166
Patiño-García, A. (Ana)|||/items/d68c74f1-df22-4e04-9b77-9cf48fd87b46
Alonso-Roldán, M.M. (Marta María)|||/items/b912e21e-f895-4efe-bc4c-de1ca8f36c37
author Martinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559
author_facet Martinez-Velez, N. (Naiara)|||/items/691b094b-c17c-4084-be40-caea58286559
Laspidea, V. (Virginia)|||/items/16d4f649-0742-47dc-a391-881d6cfb978f
Zalacain-Díez, M. (Marta)|||/items/c9a0a606-4b28-4f43-b423-2bd8ca984432
Labiano-Almiñana, S. (Sara)|||/items/65de3442-2f0f-4c20-8e40-43525bb58657
Garcia-Moure, M. (Marc)|||/items/9741d07b-2525-4e98-9bfc-93fc3e869273
Puigdelloses-Vallcorba, M. (Montserrat)|||/items/658120d0-6a3c-4bf3-9446-33a9234f787e
Marrodán-Fernández, L. (Lucía)|||/items/cb588714-8640-4468-a1e4-ea467d9fe714
Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40b
Herrador-Cañete, G. (Guillermo)|||/items/91f6f4a9-1383-4ec6-b17f-a914248ff8b0
Nava-Martín, D. (Daniel) de la|||/items/9d3a254f-7e46-4632-8066-48e55de9acbd
Ausejo-Mauleón, I. (Iker)|||/items/5dc64e9f-8695-4947-a007-886bda06f2a5
Fueyo, J. (Juan)|||/items/a4e5ff79-2565-4461-ab26-34868ff5ff4d
Gomez-Manzano, C. (Candelaria)|||/items/5e8d7495-6be8-46e1-8303-cfd722d30166
Patiño-García, A. (Ana)|||/items/d68c74f1-df22-4e04-9b77-9cf48fd87b46
Alonso-Roldán, M.M. (Marta María)|||/items/b912e21e-f895-4efe-bc4c-de1ca8f36c37
author_role author
author2 Laspidea, V. (Virginia)|||/items/16d4f649-0742-47dc-a391-881d6cfb978f
Zalacain-Díez, M. (Marta)|||/items/c9a0a606-4b28-4f43-b423-2bd8ca984432
Labiano-Almiñana, S. (Sara)|||/items/65de3442-2f0f-4c20-8e40-43525bb58657
Garcia-Moure, M. (Marc)|||/items/9741d07b-2525-4e98-9bfc-93fc3e869273
Puigdelloses-Vallcorba, M. (Montserrat)|||/items/658120d0-6a3c-4bf3-9446-33a9234f787e
Marrodán-Fernández, L. (Lucía)|||/items/cb588714-8640-4468-a1e4-ea467d9fe714
Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40b
Herrador-Cañete, G. (Guillermo)|||/items/91f6f4a9-1383-4ec6-b17f-a914248ff8b0
Nava-Martín, D. (Daniel) de la|||/items/9d3a254f-7e46-4632-8066-48e55de9acbd
Ausejo-Mauleón, I. (Iker)|||/items/5dc64e9f-8695-4947-a007-886bda06f2a5
Fueyo, J. (Juan)|||/items/a4e5ff79-2565-4461-ab26-34868ff5ff4d
Gomez-Manzano, C. (Candelaria)|||/items/5e8d7495-6be8-46e1-8303-cfd722d30166
Patiño-García, A. (Ana)|||/items/d68c74f1-df22-4e04-9b77-9cf48fd87b46
Alonso-Roldán, M.M. (Marta María)|||/items/b912e21e-f895-4efe-bc4c-de1ca8f36c37
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Oncolytic Adenovirus
Osteosarcoma
Delta-24-ACT
topic Oncolytic Adenovirus
Osteosarcoma
Delta-24-ACT
description Osteosarcoma is an aggressive bone tumor occurring primarily in pediatric patients. Despite years of intensive research, the outcomes of patients with metastatic disease or those who do not respond to therapy have remained poor and have not changed in the last 30 years. Oncolytic virotherapy is becoming a reality to treat local and metastatic tumors while maintaining a favorable safety profile. Delta-24-ACT is a replicative oncolytic adenovirus engineered to selectively target cancer cells and to potentiate immune responses through expression of the immune costimulatory ligand 4-1BB. This work aimed to assess the antisarcoma effect of Delta-24-ACT. MTS and replication assays were used to quantify the antitumor effects of Delta-24-ACT in vitro in osteosarcoma human and murine cell lines. Evaluation of the in vivo antitumor effect and immune response to Delta-24-ACT was performed in immunocompetent mice bearing the orthotopic K7M2 cell line. Immunophenotyping of the tumor microenvironment was characterized by immunohistochemistry and flow cytometry. In vitro, Delta-24-ACT killed osteosarcoma cells and triggered the production of danger signals. In vivo, local treatment with Delta-24-ACT led to antitumor effects against both the primary tumor and spontaneous metastases in a murine osteosarcoma model. Viral treatment was safe, with no noted toxicity. Delta-24-ACT significantly increased the median survival time of treated mice. Collectively, our data identify Delta-24-ACT administration as an effective and safe therapeutic strategy for patients with local and metastatic osteosarcoma. These results support clinical translation of this viral immunotherapy approach.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/116490
url https://hdl.handle.net/10171/116490
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Association for Cancer Research
publisher.none.fl_str_mv American Association for Cancer Research
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418571640078336
score 15,811543